{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "wsmg:health-sciences/medicine/hematology/hem-019",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:58:35.000Z",
    "modified": "2026-01-11T02:50:00.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "quality-agent"
    ],
    "confidence": 0.96,
    "status": "validated",
    "language": "en",
    "licenses": [
      "CC-BY-4.0"
    ]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/hematology",
    "subdomain": "plasma-cell-dyscrasias",
    "type": "definition",
    "difficulty": "advanced",
    "importance": "critical",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Multiple Myeloma",
    "summary": "Multiple myeloma (MM) is a malignant plasma cell neoplasm characterized by clonal bone marrow plasma cells producing monoclonal immunoglobulin (M-protein). It causes end-organ damage (CRAB: Calcium elevation, Renal insufficiency, Anemia, Bone disease). Treatment involves triplet regimens (proteasome inhibitor + IMiD + steroid) and autologous stem cell transplant in eligible patients.",
    "key_points": [
      "Definition: ≥10% clonal bone marrow plasma cells OR biopsy-proven plasmacytoma + myeloma-defining event",
      "CRAB criteria: Calcium >11, Renal (Cr >2), Anemia (Hgb <10), Bone lesions",
      "SLiM criteria: 60% plasma cells, involved/uninvolved FLC ratio ≥100, >1 focal lesion on MRI",
      "M-protein: SPEP + SFLC for diagnosis and monitoring",
      "Treatment: VRd (bortezomib-lenalidomide-dex) → ASCT if eligible; daratumumab increasingly first-line",
      "Supportive: bisphosphonates, infection prophylaxis, thromboprophylaxis"
    ],
    "statement": "Multiple myeloma is a clonal plasma cell malignancy producing monoclonal immunoglobulin with end-organ damage (CRAB) diagnosed by bone marrow biopsy and serum/urine protein electrophoresis, treated with proteasome inhibitor-based triplet regimens and autologous stem cell transplant in eligible patients.",
    "explanation": {
      "intuition": "Plasma cells are antibody factories. In myeloma, a single plasma cell clone multiplies uncontrollably, crowding the bone marrow (→anemia), destroying bone (→fractures, hypercalcemia), and producing excessive antibody protein that damages kidneys (→renal failure).",
      "key_insight": "The CRAB criteria identify symptomatic myeloma requiring treatment. The newer SLiM criteria identify high-risk 'smoldering' myeloma that should also be treated despite absent CRAB features because progression is imminent.",
      "technical_details": "M-protein is detected by SPEP (serum protein electrophoresis) as a monoclonal spike. Immunofixation identifies the heavy and light chain type (IgG kappa is most common). Free light chain assay is essential for light-chain-only myeloma. t(11;14), t(4;14), del(17p), and +1q are important cytogenetics."
    },
    "definitions_glossary": {
      "multiple_myeloma": "Clonal plasma cell neoplasm producing monoclonal immunoglobulin with end-organ damage",
      "M_protein": "Monoclonal immunoglobulin or light chain produced by myeloma cells",
      "CRAB": "Calcium, Renal, Anemia, Bone - end-organ damage criteria",
      "SLiM": "Sixty percent plasma cells, Light chain ratio ≥100, MRI lesions >1 - biomarkers of imminent progression",
      "SPEP": "Serum protein electrophoresis; detects monoclonal protein spike",
      "SFLC": "Serum free light chain assay; detects kappa or lambda light chains",
      "proteasome_inhibitor": "Drug class blocking proteasome (bortezomib, carfilzomib, ixazomib)",
      "IMiD": "Immunomodulatory drug (lenalidomide, pomalidomide, thalidomide)",
      "ASCT": "Autologous stem cell transplant; consolidation after induction",
      "MGUS": "Monoclonal gammopathy of undetermined significance; precursor lesion",
      "smoldering_myeloma": "Clonal plasma cells with M-protein but no CRAB; watch or treat if SLiM",
      "daratumumab": "Anti-CD38 monoclonal antibody; increasingly first-line in myeloma"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "mechanism": "Clonal plasma cell proliferation → M-protein production → hyperviscosity, renal damage; bone destruction via osteoclast activation; bone marrow crowding → cytopenias"
    },
    "clinical_manifestations": {
      "CRAB": {
        "C": "Hypercalcemia (bone resorption)",
        "R": "Renal insufficiency (light chain cast nephropathy)",
        "A": "Anemia (marrow replacement)",
        "B": "Bone disease (lytic lesions, fractures)"
      },
      "other": [
        "Infections (antibody deficiency)",
        "Hyperviscosity (IgA, IgG3)",
        "Amyloidosis (AL)"
      ]
    },
    "diagnostic_criteria": {
      "IMWG_2014": {
        "requirement": "≥10% clonal plasma cells OR plasmacytoma AND myeloma-defining event",
        "myeloma_defining_events": {
          "CRAB": [
            "Ca >11 mg/dL",
            "Cr >2 mg/dL or CrCl <40",
            "Hgb <10 g/dL",
            "≥1 lytic bone lesion"
          ],
          "SLiM": [
            "≥60% bone marrow plasma cells",
            "FLC ratio ≥100",
            ">1 focal lesion on MRI"
          ]
        }
      },
      "workup": [
        "CBC, BMP, calcium, LDH",
        "SPEP, UPEP, immunofixation, SFLC",
        "Bone marrow biopsy with cytogenetics/FISH",
        "Skeletal survey or whole-body low-dose CT or PET-CT"
      ]
    },
    "differential_diagnosis": [
      "MGUS (M-protein <3 g/dL, <10% plasma cells, no CRAB)",
      "Smoldering myeloma (≥10% plasma cells but no CRAB/SLiM)",
      "Waldenström macroglobulinemia (IgM, lymphoplasmacytic)",
      "AL amyloidosis (light chain deposition)"
    ],
    "treatment_options": {
      "induction": {
        "transplant_eligible": "VRd (bortezomib-lenalidomide-dex) × 3-4 cycles; Dara-VRd increasingly used",
        "transplant_ineligible": "VRd or Dara-Rd until progression; similar regimens, longer duration"
      },
      "transplant": {
        "ASCT": "High-dose melphalan followed by autologous stem cell rescue; deepens response"
      },
      "maintenance": {
        "standard": "Lenalidomide until progression",
        "high_risk": "Consider bortezomib-based maintenance"
      },
      "supportive": {
        "bone": "Zoledronic acid or denosumab",
        "infection": "Vaccination; acyclovir/valacyclovir prophylaxis",
        "renal": "Avoid NSAIDs, nephrotoxins; hydration",
        "thromboprophylaxis": "Aspirin or anticoagulation with IMiDs"
      }
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Multiple Myeloma"
    },
    "altLabel": [
      {
        "@language": "en",
        "@value": "Plasma cell myeloma"
      },
      {
        "@language": "en",
        "@value": "Kahler disease"
      }
    ],
    "definition": {
      "@language": "en",
      "@value": "A clonal plasma cell malignancy producing monoclonal immunoglobulin (M-protein) causing CRAB end-organ damage"
    },
    "notation": "hem-019"
  },
  "relationships": {
    "skos:broader": [
      {
        "@id": "wsmg:health-sciences/medicine/hematology/plasma-cell-dyscrasias",
        "skos:prefLabel": "Plasma Cell Dyscrasias"
      }
    ],
    "skos:related": [
      {
        "@id": "wsmg:health-sciences/medicine/hematology/hem-020",
        "skos:prefLabel": "Monoclonal Gammopathy of Undetermined Significance"
      }
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "109989006",
      "uri": "http://snomed.info/id/109989006",
      "description": "Multiple myeloma"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "C90.0",
      "uri": "http://hl7.org/fhir/sid/icd-10-cm/C90.0",
      "description": "Multiple myeloma"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D009101",
      "uri": "http://id.nlm.nih.gov/mesh/D009101",
      "description": "Multiple Myeloma"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Apply CRAB and SLiM criteria for diagnosis",
      "Interpret serum protein electrophoresis and free light chains",
      "Select appropriate induction therapy based on transplant eligibility",
      "Recognize high-risk cytogenetics"
    ],
    "clinical_pearls": [
      "Check SFLC even if SPEP normal - 15% are light-chain-only myeloma",
      "Whole-body low-dose CT replacing skeletal survey - finds more lesions",
      "High-risk cytogenetics: t(4;14), t(14;16), del(17p), +1q - shorter remissions",
      "Daratumumab added to VRd (Dara-VRd) improves MRD negativity and PFS"
    ],
    "board_yield": "HIGH",
    "estimated_time": "30min",
    "target_audience": [
      "internal_medicine_residents",
      "hematology_fellows"
    ]
  },
  "prerequisites": [
    {
      "@id": "wsmg:health-sciences/medicine/hematology/hem-020",
      "skos:prefLabel": "MGUS"
    }
  ],
  "related_concepts": [
    "M-protein",
    "proteasome inhibitor",
    "ASCT",
    "CRAB criteria",
    "free light chains"
  ],
  "evidence": {
    "citations": [
      {
        "authors": "Rajkumar SV, Dimopoulos MA, Palumbo A, et al.",
        "title": "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma",
        "journal": "Lancet Oncol",
        "year": 2014,
        "volume": "15",
        "pages": "e538-e548",
        "doi": "10.1016/S1470-2045(14)70442-5"
      }
    ],
    "confidence_rationale": "IMWG diagnostic criteria and NCCN treatment guidelines"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T02:50:00.000Z",
    "sources": [
      {
        "source": "IMWG 2014 Diagnostic Criteria",
        "type": "guideline",
        "year": 2014,
        "relevance": "Primary diagnostic criteria"
      }
    ]
  },
  "quality_assessment": {
    "content_quality_score": 0.95,
    "completeness": 0.96,
    "accuracy": 0.96,
    "clarity": 0.94,
    "clinical_relevance": 0.97,
    "last_assessed": "2026-01-11T02:50:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Multiple_myeloma",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q176780"
}